Improving Response Inhibition in Parkinson’s Disease with Atomoxetine

BACKGROUND: Dopaminergic drugs remain the mainstay of Parkinson’s disease therapy but often fail to improve cognitive problems such as impulsivity. This may be due to the loss of other neurotransmitters, including noradrenaline, which is linked to impulsivity and response inhibition. We therefore ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Zheng, Altena, Ellemarije, Nombela, Cristina, Housden, Charlotte R., Maxwell, Helen, Rittman, Timothy, Huddleston, Chelan, Rae, Charlotte L., Regenthal, Ralf, Sahakian, Barbara J., Barker, Roger A., Robbins, Trevor W., Rowe, James B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Archival Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384955/
https://www.ncbi.nlm.nih.gov/pubmed/24655598
http://dx.doi.org/10.1016/j.biopsych.2014.01.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384955/
https://www.ncbi.nlm.nih.gov/pubmed/24655598
http://dx.doi.org/10.1016/j.biopsych.2014.01.024

Ejemplares similares